Inhibition effect of staphylokinase mutant SRH on the development of SHR rat's Atherosclerosis

The effect of SRH on development of atherosclerosis in SHR rats fed on high fat diet was investigated, in order to obtain reliable evidence for the possibility of further clinical application. SRH was taken intravenously by healthy rats and high fat diet SHR rats in the same dosage (0.5 mg/kg) for 20 days (once two days). The clinical hemorrhagic manifestations were observed and a set of hemostatic tests ( ATPP, PT, TT, Fg) , blood fat (TG, TC, LDL-C, HDL), and fibrinolytic systems tests (PLG, PI, FDP, D-D), electrocardiogram and blood pressure were monitored before and after injection. None of them showed visceral bleeding and gingival bleeding. There were no significant changes in WKY fibrinolytic and coagulative phases. It was supported that SRH was a highly selective fibrirolytic agent without significant influence on rat hemostatic and coagulatic systems. While, SRH can decrease the high thromboxane states of high diet fat SHR rats and the blood fat levels of high diet fat SHR rats, and it can release the blood pressure and weaken vessel wall lesion. The SRH is a relatively safe and well tolerated agent for healthy and atherosclerosis rats, and it contributes to inhibit the progression of SHR's atherosclerosis.